Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IS NAVOBAN(R) (TROPISETRON) AS EFFECTIVE AS ZOFRAN(R) (ONDANSETRON) IN CISPLATIN-INDUCED EMESIS
Autore:
MARTY M; KLEISBAUER JP; FOURNEL P; VERGNENEGRE A; CARLES P; LORIAKANZA Y; SIMONETTA C; DEBRUIJN KM; LAURAINE P; DIDIER A; CUPISSOL D; BERGERAT JP; PUJAZON MC; HERON JF; DRENO B; TAYTARD A; GUERIN JC; CLAVIER J; ROBINET G; BLANCHON F; BALMES P; MUIR JF; PAILLOTIN D; POIRIER R; BONNETERRE J; MELLONI B; ROCHE H; DEPIERRE A; PLAGNE R; SOUQUET PJ; ARMAND JP; DEFORNI M;
Indirizzi:
HOP ST LOUIS,1 AVE CLAUDE VELLEFAUX F-75010 PARIS FRANCE HOP ST MARGUERITE MARSEILLE FRANCE HOP NORD ST PRIEST FRANCE CHRU CLUZEAU LIMOGES FRANCE HOP PURPAN TOULOUSE FRANCE LABS SANDOZ RUEIL MALMAISON FRANCE SANDOZ PHARMA LTD CH-4002 BASEL SWITZERLAND HOP HOTEL DIEU F-75181 PARIS FRANCE HOP RANGUEIL TOULOUSE FRANCE INST CANC RES MONTPELLIER FRANCE HOSP CIVILES STRASBOURG FRANCE CTR FRANCOIS BACLESSE F-14021 CAEN FRANCE HOP HOTEL DIEU NANTES FRANCE HOP HAUT LEVEQUE PESSAC FRANCE HOP CROIX ROUSSE F-69317 LYON FRANCE HOP MORVAN BREST FRANCE CTR HOSP MEAUX FRANCE CTR HOSP NIMES FRANCE CTR HOSP BOIS GUILLAUME FRANCE CTR HOSP AIX EN PROVENCE FRANCE CTR OSCAR LAMBRET F-59020 LILLE FRANCE CTR CLAUDIUS REGAUD TOULOUSE FRANCE HOP ST JACQUES F-25030 BESANCON FRANCE CTR ANTICANCEREUX JEAN PERRIN CLERMONT FERRAND FRANCE CTR HOSP LYON SUD LYON BENITE FRANCE INST GUSTAVE ROUSSY VILLEJUIF FRANCE
Titolo Testata:
Anti-cancer drugs
, volume: 6, anno: 1995, supplemento:, 1
pagine: 15 - 21
SICI:
0959-4973(1995)6:<15:IN(AEA>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE METOCLOPRAMIDE; INDUCED NAUSEA; DOUBLE-BLIND; EFFICACY; CHEMOTHERAPY; PREVENTION; TRIALS;
Keywords:
NAVOBAN(R) (TROPISETRON); ZOFRAN(R) (ONDANSETRON); EMESIS; VOMITING; NAUSEA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
M. Marty et al., "IS NAVOBAN(R) (TROPISETRON) AS EFFECTIVE AS ZOFRAN(R) (ONDANSETRON) IN CISPLATIN-INDUCED EMESIS", Anti-cancer drugs, 6, 1995, pp. 15-21

Abstract

The purpose of this study was to evaluate and com pare the antiemeticeffectiveness and tolerability of Navoban(R)(tropisetron) and Zofran(R) (ondansetron) following high-dose (greater than or equal to 50 mg/m(2)) cisplatin chemotherapy. In a randomised, multicentre, double-biind, double-dummy, parallel group study, 117 evaluable chemotherapy-naive patients who received Navoban(R) were compared with 114 who receivedZofran(R). Patient diary cards were used to assess both acute (Day 1)and delayed (Days 2-6) nausea and vomiting. Total control of acute vomiting was achieved in 54% of Navoban(R) and 65% of Zofran(R) patients(p = 0.052), and total control of acute nausea in 66% and 62% respectively (p = 0.655). Total control of delayed vomiting was achieved in 44% of Navoban(R) patients and 46% of Zofran(R) patients (p = 0.765), and of delayed nausea in 56% and 47% respectively (p = 0.207). Bath reactions combined were totally prevented during the entire 6-day trial period in 22% of Navoban(R) and 24% of Zofran(R) patients (NS), while afurther 42% of patients in both groups remained largely free from both nausea and emesis. The few adverse reactions (e.g. headache, constipation, diarrhoea) were mainly mild and typical of the 5-HT3-receptor antagonists. In conclusion, there were no significant differences in efficacy and tolerability between Navoban(R) 5 mg once daily and the highest recommended dose of Zofran(R) (32 mg on Day 1, followed by 8 mg three times a day).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 17:04:24